Evidence map›Paper›PMID 38963938›Full record

ArticleGlycobiology2024

Identification of heparin-binding amino acid residues in antibody HS4C3 with the potential to design antibodies against heparan sulfate domains.

Lars A A Damen, Thao P Bui, Thierry van Wessel, Yong Li, Bart F Straten, Robin Pampiermole, Willeke F Daamen, David G Fernig, Toin H van Kuppevelt

Abstract read
In one paragraph

Article in Glycobiology, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed.

  1. Article
  2. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors.

Lars A A DamenDepartment of Medical BioSciences, Radboud Institute for Medical Innovation, Radboud University Medical Center, PO Box 9101, Nijmegen 6500 HB, the Netherlands.ORCID 0000-0001-7018-7702
Thao P BuiDepartment of Biochemistry, Cell and Systems Biology, Institute of Systems, Molecular and Integrated Biology, University of Liverpool, Crown Street, Liverpool L69 7ZB, United Kingdom.ORCID 0000-0003-3704-734X
Thierry van WesselDepartment of Medical BioSciences, Radboud Institute for Medical Innovation, Radboud University Medical Center, PO Box 9101, Nijmegen 6500 HB, the Netherlands.ORCID 0000-0001-7258-1404
Yong LiDepartment of Biochemistry, Cell and Systems Biology, Institute of Systems, Molecular and Integrated Biology, University of Liverpool, Crown Street, Liverpool L69 7ZB, United Kingdom.ORCID 0000-0002-5594-4434
Bart F StratenDepartment of Medical BioSciences, Radboud Institute for Medical Innovation, Radboud University Medical Center, PO Box 9101, Nijmegen 6500 HB, the Netherlands.ORCID 0000-0002-6750-5914
Robin PampiermoleDepartment of Medical BioSciences, Radboud Institute for Medical Innovation, Radboud University Medical Center, PO Box 9101, Nijmegen 6500 HB, the Netherlands.ORCID 0000-0003-4964-3923
Willeke F DaamenDepartment of Medical BioSciences, Radboud Institute for Medical Innovation, Radboud University Medical Center, PO Box 9101, Nijmegen 6500 HB, the Netherlands.ORCID 0000-0003-3155-3030
David G FernigDepartment of Biochemistry, Cell and Systems Biology, Institute of Systems, Molecular and Integrated Biology, University of Liverpool, Crown Street, Liverpool L69 7ZB, United Kingdom.ORCID 0000-0003-4875-4293
Toin H van KuppeveltDepartment of Medical BioSciences, Radboud Institute for Medical Innovation, Radboud University Medical Center, PO Box 9101, Nijmegen 6500 HB, the Netherlands.ORCID 0000-0002-7028-6783

Funding

ArrestADEuropean UnionGovernment Scholarship for Training Lecturers for Universities in Vietnam 911H2020-FETOPEN 737390H2020-FETOPEN 899687HS-SEQ
6 · The paper itself

Abstract

Heparan sulfate (HS) is a linear polysaccharide with high structural and functional diversity. Detection and localization of HS in tissues can be performed using single chain variable fragment (scFv) antibodies. Although several anti-HS antibodies recognizing different sulfation motifs have been identified, little is known about their interaction with HS. In this study the interaction between the scFv antibody HS4C3 and heparin was investigated. Heparin-binding lysine and arginine residues were identified using a protect and label methodology. Site-directed mutagenesis was applied to further identify critical heparin-binding lysine/arginine residues using immunohistochemical and biochemical assays. In addition, computational docking of a heparin tetrasaccharide towards a 3-D homology model of HS4C3 was applied to identify potential heparin-binding sites. Of the 12 lysine and 15 arginine residues within the HS4C3 antibody, 6 and 9, respectively, were identified as heparin-binding. Most of these residues are located within one of the complementarity determining regions (CDR) or in their proximity. All basic amino acid residues in the CDR3 region of the heavy chain were involved in binding. Computational docking showed a heparin tetrasaccharide close to these regions. Mutagenesis of heparin-binding residues reduced or altered reactivity towards HS and heparin. Identification of heparin-binding arginine and lysine residues in HS4C3 allows for better understanding of the interaction with HS and creates a framework to rationally design antibodies targeting specific HS motifs.

Indexed as

Heparan SulfateHeparinAmino Acid SequenceAnimalsBinding SitesHumansMolecular Docking SimulationMutagenesis, Site-DirectedSingle-Chain AntibodiesHeparan SulfateHeparinSingle-Chain Antibodiesantibodiesheparan sulfateheparin-binding residuesprotect & labelsite-specific mutations

Identifiers

PMID38963938
PMCPMC11231949

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.